Loading...

Emerald Health Therapeutics

OTCPK:EMHT.F
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EMHT.F
OTCPK
CA$569M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis in Canada. The last earnings update was 148 days ago. More info.


Add to Portfolio Compare Print
  • Emerald Health Therapeutics has significant price volatility in the past 3 months.
EMHT.F Share Price and Events
7 Day Returns
4.9%
OTCPK:EMHT.F
-0.9%
US Pharmaceuticals
0.9%
US Market
1 Year Returns
-16.1%
OTCPK:EMHT.F
8.5%
US Pharmaceuticals
9.6%
US Market
EMHT.F Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Emerald Health Therapeutics (EMHT.F) 4.9% -3.2% 35% -16.1% 1663.6% -
US Pharmaceuticals -0.9% -3.7% 0.2% 8.5% 8.3% 14.3%
US Market 0.9% 4.6% 10.9% 9.6% 39% 47.2%
1 Year Return vs Industry and Market
  • EMHT.F underperformed the Pharmaceuticals industry which returned 8.5% over the past year.
  • EMHT.F underperformed the Market in United States of America which returned 9.6% over the past year.
Price Volatility
EMHT.F
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Emerald Health Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Emerald Health Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Emerald Health Therapeutics.

OTCPK:EMHT.F Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OTCPK:EMHT.F
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.68
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.676 (1 + (1- 26.5%) (0.45%))
0.784
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for OTCPK:EMHT.F using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Emerald Health Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OTCPK:EMHT.F DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 7.5%)
2019 -21.00 Analyst x1 -19.54
2020 -18.00 Analyst x1 -15.58
2021 -22.00 Analyst x1 -17.71
2022 0.00 Analyst x1 0.00
2023 10.00 Analyst x1 6.97
2024 16.02 Est @ 60.22% 10.38
2025 22.91 Est @ 42.97% 13.81
2026 29.98 Est @ 30.9% 16.82
2027 36.72 Est @ 22.45% 19.15
2028 42.79 Est @ 16.53% 20.76
Present value of next 10 years cash flows CA$35.07
OTCPK:EMHT.F DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= CA$42.79 × (1 + 2.73%) ÷ (7.5% – 2.73%)
CA$921.86
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$921.86 ÷ (1 + 7.5%)10
CA$447.36
OTCPK:EMHT.F Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$35.07 + CA$447.36
CA$482.43
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$482.43 / 143.92
CA$3.35
OTCPK:EMHT.F Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in OTCPK:EMHT.F represents 0.73671x of TSXV:EMH
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.73671x
Value per Share
(Listing Adjusted, USD)
= Value per Share (CAD) x Listing Adjustment Factor
= CA$ 3.35 x 0.73671
$2.47
Value per share (USD) From above. $2.47
Current discount Discount to share price of $2.91
= -1 x ($2.91 - $2.47) / $2.47
-17.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Emerald Health Therapeutics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Emerald Health Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Emerald Health Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:EMHT.F PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in CAD CA$-0.17
TSXV:EMH Share Price ** TSXV (2019-04-25) in CAD CA$3.95
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.77x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 18.28x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Emerald Health Therapeutics.

OTCPK:EMHT.F PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:EMH Share Price ÷ EPS (both in CAD)

= 3.95 ÷ -0.17

-22.94x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Emerald Health Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Emerald Health Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Emerald Health Therapeutics's expected growth come at a high price?
Raw Data
OTCPK:EMHT.F PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -22.94x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
94.5%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 23 Publicly-Listed Pharmaceuticals Companies 1.51x
United States of America Market PEG Ratio Median Figure of 2,113 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Emerald Health Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Emerald Health Therapeutics's assets?
Raw Data
OTCPK:EMHT.F PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in CAD CA$1.26
TSXV:EMH Share Price * TSXV (2019-04-25) in CAD CA$3.95
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 3.52x
United States of America Market PB Ratio Median Figure of 5,185 Publicly-Listed Companies 1.92x
OTCPK:EMHT.F PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:EMH Share Price ÷ Book Value per Share (both in CAD)

= 3.95 ÷ 1.26

3.14x

* Primary Listing of Emerald Health Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Emerald Health Therapeutics is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Emerald Health Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Emerald Health Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Emerald Health Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
94.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Emerald Health Therapeutics expected to grow at an attractive rate?
  • Emerald Health Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Emerald Health Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Emerald Health Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
OTCPK:EMHT.F Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:EMHT.F Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 94.5%
OTCPK:EMHT.F Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 85.3%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:EMHT.F Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:EMHT.F Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 37 33 37 1
2020-12-31 70 17 17 2
2019-12-31 4 1 2 1
2018-12-31 2 -13 -17 1
OTCPK:EMHT.F Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-09-30 1 -20 -21
2018-06-30 1 -15 -16
2018-03-31 1 -10 -12
2017-12-31 1 -8 -9
2017-09-30 1 -5 -6
2017-06-30 1 -4 -5
2017-03-31 0 -3 -4
2016-12-31 0 -2 -3
2016-09-30 0 -2 -3
2016-06-30 0 -2 -2
2016-03-31 0 -2 -3
2015-12-31 0 -2 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Emerald Health Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Emerald Health Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:EMHT.F Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Emerald Health Therapeutics Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:EMHT.F Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.27 0.27 0.27 1.00
2020-12-31 0.13 0.13 0.13 1.00
2019-12-31 0.01 0.01 0.01 1.00
2018-12-31 -0.12 -0.12 -0.12 1.00
OTCPK:EMHT.F Past Financials Data
Date (Data in CAD Millions) EPS *
2018-09-30 -0.17
2018-06-30 -0.15
2018-03-31 -0.13
2017-12-31 -0.10
2017-09-30 -0.07
2017-06-30 -0.07
2017-03-31 -0.06
2016-12-31 -0.05
2016-09-30 -0.05
2016-06-30 -0.05
2016-03-31 -0.07
2015-12-31 -0.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Emerald Health Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Emerald Health Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Emerald Health Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Emerald Health Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Emerald Health Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Emerald Health Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Emerald Health Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Emerald Health Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Emerald Health Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Emerald Health Therapeutics Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:EMHT.F Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 1.26 -20.59 24.79 0.31
2018-06-30 1.15 -16.19 16.84 0.25
2018-03-31 1.11 -12.43 12.09 0.26
2017-12-31 0.94 -8.73 8.32 0.21
2017-09-30 0.78 -5.69 4.94 0.22
2017-06-30 0.62 -4.77 4.07 0.26
2017-03-31 0.41 -3.64 2.87 0.24
2016-12-31 0.25 -2.94 2.13 0.30
2016-09-30 0.15 -2.60 1.89 0.34
2016-06-30 0.11 -2.30 1.62 0.33
2016-03-31 0.07 -3.22 2.68 0.27
2015-12-31 0.03 -3.50 3.11 0.16
2015-09-30 0.01 -3.71 3.38 0.11
2015-06-30 -4.41 3.59 0.05
2015-03-31 -3.39 2.57 0.04
2014-12-31 -2.65 1.84 0.04
2014-09-30 -1.91 1.15 0.00
2014-06-30 -0.50 0.44
2013-12-31 -0.02 0.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Emerald Health Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Emerald Health Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Emerald Health Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Emerald Health Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Emerald Health Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Emerald Health Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Emerald Health Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Emerald Health Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Emerald Health Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Emerald Health Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 27.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Emerald Health Therapeutics Company Filings, last reported 6 months ago.

OTCPK:EMHT.F Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 171.90 2.54 52.91
2018-06-30 177.98 2.56 72.68
2018-03-31 119.73 0.00 89.50
2017-12-31 67.79 0.00 44.52
2017-09-30 37.70 0.00 22.82
2017-06-30 39.35 0.00 36.16
2017-03-31 15.26 0.00 14.75
2016-12-31 3.70 0.00 3.22
2016-09-30 1.24 0.33 0.88
2016-06-30 -0.01 0.67 0.01
2016-03-31 -0.89 1.53 0.01
2015-12-31 -0.41 0.00 0.08
2015-09-30 0.08 0.35 0.07
2015-06-30 0.71 0.02 0.40
2015-03-31 1.30 0.02 1.07
2014-12-31 1.91 0.02 1.72
2014-09-30 2.52 0.06 2.47
2014-06-30 0.35 0.06 0.39
2013-12-31 -0.01 0.01 0.00
  • Emerald Health Therapeutics's level of debt (1.5%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Emerald Health Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Emerald Health Therapeutics has sufficient cash runway for 1.7 years based on current free cash flow.
  • Emerald Health Therapeutics has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 95.7% each year.
X
Financial health checks
We assess Emerald Health Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Emerald Health Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Emerald Health Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Emerald Health Therapeutics dividends.
If you bought $2,000 of Emerald Health Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Emerald Health Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Emerald Health Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:EMHT.F Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OTCPK:EMHT.F Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31
2018-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Emerald Health Therapeutics has not reported any payouts.
  • Unable to verify if Emerald Health Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Emerald Health Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Emerald Health Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Emerald Health Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Emerald Health Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Emerald Health Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Emerald Health Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Emerald Health Therapeutics has no CEO, or we have no data on them.
Management Team Tenure

Average tenure of the Emerald Health Therapeutics management team in years:

0.4
Average Tenure
  • The average tenure for the Emerald Health Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Avtar Dhillon

TITLE
Executive Chairman & President
COMPENSATION
CA$45K
AGE
56
TENURE
0.4 yrs

Rob Hill

TITLE
CFO & Corporate Secretary
COMPENSATION
CA$196K
TENURE
1.4 yrs

Chris Wagner

TITLE
Consultant
COMPENSATION
CA$253K
AGE
49
TENURE
0.4 yrs

Michael Bierman

TITLE
Vice President of Operations
TENURE
1.3 yrs

Allan Rewak

TITLE
Vice President of Communications & Stakeholder Relations

Thierry Schmidt

TITLE
President of Agro-Biotech
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure and age of the Emerald Health Therapeutics board of directors in years:

4
Average Tenure
52
Average Age
  • The tenure for the Emerald Health Therapeutics board of directors is about average.
Board of Directors

Avtar Dhillon

TITLE
Executive Chairman & President
COMPENSATION
CA$45K
AGE
56
TENURE
4 yrs

Jim Heppell

TITLE
Director
COMPENSATION
CA$33K
AGE
62
TENURE
4 yrs

Punit Dhillon

TITLE
Director
COMPENSATION
CA$37K
AGE
38
TENURE
4 yrs

Bob Rai

TITLE
Director
COMPENSATION
CA$30K
AGE
48
TENURE
2.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
23. Jan 19 Sell Emerald Health Sciences Inc. Company 16. Jan 19 16. Jan 19 -2,800,000 $1.89 $-5,286,929
31. May 18 Sell Emerald Health Sciences Inc. Company 22. May 18 22. May 18 -2,000,000 $3.29 $-6,573,388
X
Management checks
We assess Emerald Health Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Emerald Health Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis in Canada. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Victoria, Canada.

Details
Name: Emerald Health Therapeutics, Inc.
EMHT.F
Exchange: OTCPK
Founded:
CA$421,290,409
143,924,536
Website: http://emeraldhealth.ca
Address: Emerald Health Therapeutics, Inc.
4420 West Saanich Road,
PO Box 24076,
Victoria,
British Columbia, V8Z 7E7,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV EMH Common Shares TSX Venture Exchange CA CAD 08. Sep 2014
OTCPK EMHT.F Common Shares Pink Sheets LLC US USD 08. Sep 2014
DB TBD Common Shares Deutsche Boerse AG DE EUR 08. Sep 2014
Number of employees
Current staff
Staff numbers
25
Emerald Health Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/26 03:06
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2018/11/29
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.